会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明授权
    • Method and apparatus for reduction of metal oxides
    • 用于还原金属氧化物的方法和装置
    • US4765828A
    • 1988-08-23
    • US64105
    • 1987-06-19
    • George R. Nehls, Jr.Scott D. Anderson
    • George R. Nehls, Jr.Scott D. Anderson
    • C22B4/00
    • C22B4/005
    • A method of reducing metal oxides comprises introducing feedstock material into a plasma torch reactor according to two different flow patterns. A primary feedstock is fed into the immediate vicinity of the plasma stream in a helical pattern surrounding the plasma stream. The primary feedstock material preferably comprises the metal oxides to be reduced within the reactor. A secondary feedstock material is fed at a more remote location, preferably in a flow pattern developing a protective wall for the inside of the reactor. A preferred assembly is provided for application of the process. For the preferred embodiment, the assembly comprises a top plate, a central ramp, a bottom plate and a liner to form separate feed channels for the primary and secondary feedstock.
    • 还原金属氧化物的方法包括根据两种不同的流动模式将原料引入等离子体炬反应器中。 主要原料以围绕等离子体流的螺旋图案供给到等离子体流的紧邻附近。 主要原料优选包含在反应器内待还原的金属氧化物。 次级原料在更远的位置进料,优选以流动方式进料,以形成反应器内部的保护壁。 提供了一种优选的组件来应用该方法。 对于优选实施例,组件包括顶板,中心斜面,底板和衬套,以形成用于初级和次级原料的分开的进料通道。
    • 4. 发明授权
    • Process for sizing prednisolone acetate using a supercritical fluid
anti-solvent
    • 使用超临界流体抗溶剂调节醋酸泼尼松龙的方法
    • US5803966A
    • 1998-09-08
    • US551549
    • 1995-11-01
    • Alok K. KulshreshthaGarnet G. SmithScott D. AndersonVal J. Krukonis
    • Alok K. KulshreshthaGarnet G. SmithScott D. AndersonVal J. Krukonis
    • A61K9/14A61K9/16G03B7/00
    • A61K9/1688A61K9/14
    • A process employing a supercritical fluid anti-solvent for sizing prednisolone acetate is disclosed. The process optionally incorporates sterilization filters. Average particle sizes of about 1 .mu.m or less (number average) and narrow particle size ranges are obtainable. The process comprises the steps of (a) forming a solution by dissolving prednisolone acetate in acetone such that the concentration of prednisolone acetate is approximately 80% or less of its solubility in acetone; and (b) transporting the solution formed in step (a) through an orifice having a diameter of 50-100 .mu.m into a mixer/expander containing compressed CO.sub.2, wherein the compressed CO.sub.2 is at a temperature from about 40.degree. to 80.degree. C. and has a density less than the density of the solution by at least 0.3 g/cc, to expand the solution so that the acetone dissolves in the CO.sub.2 and the prednisolone acetate precipitates.
    • 公开了一种使用超临界流体抗溶剂来定量醋酸泼尼松龙的方法。 该方法可选地包含消毒过滤器。 可获得平均粒度约1μm以下(数均)和窄粒径范围。 该方法包括以下步骤:(a)通过将丙酸泼尼松龙溶解在丙酮中形成溶液,使得醋酸泼尼松龙的浓度在丙酮中的溶解度约为80%以下; 和(b)将步骤(a)中形成的溶液通过直径为50-100μm的孔输送到含有压缩CO 2的混合器/膨胀器中,其中压缩的CO 2在约40℃至80℃的温度 并且具有小于溶液密度至少0.3g / cc的密度,以使溶液膨胀,使得丙酮溶解在CO 2中并且泼尼松龙醋酸盐沉淀。
    • 5. 发明申请
    • KEY CERTIFICATION IN ONE ROUND TRIP
    • 一次性重要认证
    • US20110099367A1
    • 2011-04-28
    • US12607937
    • 2009-10-28
    • Stefan ThomScott D. AndersonErik L. Holt
    • Stefan ThomScott D. AndersonErik L. Holt
    • H04L9/00H04L9/32
    • H04L9/3247G06F21/72H04L9/0825H04L9/0877H04L9/3234H04L9/3263H04L2209/127
    • Certification of a key, which a Trusted Platform Module (TPM) has attested as being non-migratable, can be performed in a single round trip between the certificate authority (CA) and the client that requests the certificate. The client creates a certificate request, and then has the TPM create an attestation identity key (AIK) that is bound to the certificate request. The client then asks the TPM to sign the new key as an attestation of non-migratability. The client then sends the certificate request, along with the attestation of non-migratability to the CA. The CA examines the certificate request and attestation of non-migratability. However, since the CA does not know whether the attestation has been made by a trusted TPM, it certifies the key but includes, in the certificate, an encrypted signature that can only be decrypted using the endorsement key of the trusted TPM.
    • 可信平台模块(TPM)已经证明为不可迁移的密钥的认证可以在认证机构(CA)和请求证书的客户端之间的单次往返中执行。 客户端创建证书请求,然后TPM创建绑定到证书请求的认证身份密钥(AIK)。 然后,客户要求TPM签署新的密钥,作为不可迁移性的证明。 然后,客户端将证书请求以及不可迁移性的证明发送到CA。 CA检查证书请求并证明非迁移性。 然而,由于CA不知道认证是否由受信任的TPM进行,所以它证明密钥,但是在证书中包括只能使用可信TPM的认可密钥进行解密的加密签名。
    • 6. 发明授权
    • Key certification in one round trip
    • 重要认证一次往返
    • US08700893B2
    • 2014-04-15
    • US12607937
    • 2009-10-28
    • Stefan ThomScott D. AndersonErik L. Holt
    • Stefan ThomScott D. AndersonErik L. Holt
    • H04L9/00H04L9/32
    • H04L9/3247G06F21/72H04L9/0825H04L9/0877H04L9/3234H04L9/3263H04L2209/127
    • Certification of a key, which a Trusted Platform Module (TPM) has attested as being non-migratable, can be performed in a single round trip between the certificate authority (CA) and the client that requests the certificate. The client creates a certificate request, and then has the TPM create an attestation identity key (AIK) that is bound to the certificate request. The client then asks the TPM to sign the new key as an attestation of non-migratability. The client then sends the certificate request, along with the attestation of non-migratability to the CA. The CA examines the certificate request and attestation of non-migratability. However, since the CA does not know whether the attestation has been made by a trusted TPM, it certifies the key but includes, in the certificate, an encrypted signature that can only be decrypted using the endorsement key of the trusted TPM.
    • 可信平台模块(TPM)已经证明为不可迁移的密钥的认证可以在认证机构(CA)和请求证书的客户端之间的单次往返中执行。 客户端创建证书请求,然后TPM创建绑定到证书请求的认证身份密钥(AIK)。 然后,客户要求TPM签署新的密钥,作为不可迁移性的证明。 然后,客户端将证书请求以及不可迁移性的证明发送到CA。 CA检查证书请求并证明非迁移性。 然而,由于CA不知道认证是否由受信任的TPM进行,所以它证明密钥,但是在证书中包括只能使用可信TPM的认可密钥进行解密的加密签名。
    • 7. 发明授权
    • Sample loading and handling interface to multiple chemistry analyzers
    • 多种化学分析仪的样品加载和处理接口
    • US06919044B1
    • 2005-07-19
    • US09335363
    • 1999-06-17
    • George K. ShibataPaul J. AshtonScott D. AndersonSteven D. MackSongtai Tu
    • George K. ShibataPaul J. AshtonScott D. AndersonSteven D. MackSongtai Tu
    • B32B5/02G01N35/00G01N35/04
    • G01N35/0092G01N2035/00326G01N2035/00881G01N2035/0093G01N2035/0472Y10T436/11Y10T436/113332Y10T436/114165
    • A front-end system accepts samples and selectively provides aliquots of those samples to selected clinical chemistry analyzers coupled to the front-end system. The front-end system is coupled to an assembly of one or more clinical chemistry analyzers that might, for example, provide complementary analytical tools so that the overall system of front-end system and clinical chemistry analyzers provides a predetermined broad range of clinical analytical testing. The testing protocols for samples input to the overall system can be independently determined. Any sample may undergo a test within one or more of the clinical chemistry analyzers or a series of tests within a single or more typically within plural ones of the analyzers, depending upon the testing sequence defined in for that sample. The front-end system automatically identifies samples, draws aliquots, and transports the aliquots to the one or more clinical chemistry analyzers coupled to the front-end system. Sample identification, handling and testing are preferably automated A within the overall system to provide complex testing with reduced operator involvement. Consequently, the overall system may facilitate reduced operator costs and a reduced likelihood of errors in the routing and processing of samples.
    • 前端系统接受样品并选择性地将这些样品的等分试样提供给耦合到前端系统的选定的临床化学分析仪。 前端系统耦合到一个或多个临床化学分析仪的组件,其可以例如提供补充分析工具,使得前端系统和临床化学分析仪的整个系统提供预定的广泛的临床分析测试 。 可以独立确定输入到整个系统的样本的测试协议。 任何样品可以在一种或多种临床化学分析仪中进行测试,或者根据该样品中定义的测试顺序,在一个或多个通常在多个分析仪内的一系列测试中进行测试。 前端系统自动识别样品,抽取等分试样,并将等分试样运送到耦合到前端系统的一个或多个临床化学分析仪。 样品识别,处理和测试优选在整个系统内自动化,以提供复杂的测试,减少操作员的参与。 因此,整个系统可以有助于降低运营商成本,并降低采样路由和处理中错误的可能性。